Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia
- PMID: 35538740
- DOI: 10.1111/bjh.18235
Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia
References
REFERENCES
-
- Simkins A, Maiti A, Short NJ, Jain N, Popat U, Patel KP, et al. Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2019;12(2):115-8.
-
- Ja K, My E, Lf L. Rapid progression of acquired amegakaryocytic thrombocytopenia to aplastic anemia. South Med J. 1997;90(1):91-4.
-
- Novotný JP, Köhler B, Max R, Egerer G. Acquired Amegakaryocytic thrombocytopenic purpura progressing into aplastic anemia. Prague Med Rep. 2017;118(4):147-55.
-
- Slater LM, Katz J, Walter B, Armentrout SA. Aplastic anemia occurring as amegakaryocytic thrombocytopenia with and without an inhibitor of granulopoiesis. Am J Hematol. 1985;18(3):251-4.
-
- Hoffman R, Bruno E, Elwell J, Mazur E, Gewirtz AM, Dekker P, et al. Acquired amegakaryocytic thrombocytopenic purpura: a syndrome of diverse etiologies. Blood. 1982;60(5):1173-8.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
